LOGIN  |  REGISTER
Viking Therapeutics
Terns Pharmaceuticals

ESSA Pharma to Present at the Piper Sandler 35th Annual Healthcare Conference

November 21, 2023 | Last Trade: US$1.85 0.09 5.11

SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Nov. 21, 2023 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be presenting at the Piper Sandler 35th Annual Healthcare Conference on Thursday, November 30, 2023, at 12:00 p.m. ET in New York.

David. R. Parkinson, President, and Chief Executive Officer; Peter Virsik, Chief Operating Officer; and David S. Wood, Chief Financial Officer, will host and participate in one-on-one meetings.

A live webcast of the fireside chat can be accessed in the Investors/Events & Presentations section of ESSA's website at www.essapharma.com. Following the event, the webcast will be archived on the ESSA website for 90 days.

About ESSA Pharma Inc.

ESSA is a clinical-stage pharmaceutical company focused on developing novel and proprietary therapies for the treatment of patients with prostate cancer. For more information, please visit www.essapharma.com, and follow us on Twitter and LinkedIn.

Contacts 

ESSA Pharma, Inc.
Peter Virsik, Chief Operating Officer
778.331.0962
This email address is being protected from spambots. You need JavaScript enabled to view it.

Investors and Media:
Argot Partners
212.600.1902
This email address is being protected from spambots. You need JavaScript enabled to view it.

Stock Quote

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB